WO2011126250A3 - Pde5 억제제를 함유하는 피부 주름 개선용 조성물 - Google Patents

Pde5 억제제를 함유하는 피부 주름 개선용 조성물 Download PDF

Info

Publication number
WO2011126250A3
WO2011126250A3 PCT/KR2011/002330 KR2011002330W WO2011126250A3 WO 2011126250 A3 WO2011126250 A3 WO 2011126250A3 KR 2011002330 W KR2011002330 W KR 2011002330W WO 2011126250 A3 WO2011126250 A3 WO 2011126250A3
Authority
WO
WIPO (PCT)
Prior art keywords
skin wrinkles
composition containing
pde5 inhibitor
relieving skin
containing pde5
Prior art date
Application number
PCT/KR2011/002330
Other languages
English (en)
French (fr)
Other versions
WO2011126250A2 (ko
Inventor
이수민
이수헌
류근호
이봉용
김재선
오정훈
전예지
Original Assignee
에스케이케미칼 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스케이케미칼 주식회사 filed Critical 에스케이케미칼 주식회사
Priority to CN2011800180992A priority Critical patent/CN102970965A/zh
Priority to JP2013503664A priority patent/JP2013523809A/ja
Priority to EP11766101.7A priority patent/EP2556820A4/en
Publication of WO2011126250A2 publication Critical patent/WO2011126250A2/ko
Publication of WO2011126250A3 publication Critical patent/WO2011126250A3/ko
Priority to US13/645,182 priority patent/US8716298B2/en
Priority to US14/195,372 priority patent/US9155691B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4966—Triazines or their condensed derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 피부 주름을 개선하는데 효과적인 조성물 및 이러한 조성물을 이용하는 피부 주름 개선 방법에 관한 것으로서, 포스포디에스테라제 5 (PDE5) 억제제를 유효성분으로 포함 또는 사용하는 것을 특징으로 한다.
PCT/KR2011/002330 2010-04-05 2011-04-04 Pde5 억제제를 함유하는 피부 주름 개선용 조성물 WO2011126250A2 (ko)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN2011800180992A CN102970965A (zh) 2010-04-05 2011-04-04 含有pde5抑制剂的减少皮肤皱纹的合成物
JP2013503664A JP2013523809A (ja) 2010-04-05 2011-04-04 Ｐｄｅ５抑制剤を含む皮膚しわ改善用組成物
EP11766101.7A EP2556820A4 (en) 2010-04-05 2011-04-04 COMPOSITION CONTAINING PDE5 INHIBITOR FOR MITIGATION OF SKIN WRINKLES
US13/645,182 US8716298B2 (en) 2010-04-05 2012-10-04 Composition for reducing skin wrinkles including PDE5 inhibitor
US14/195,372 US9155691B2 (en) 2010-04-05 2014-03-03 Composition for reducing skin wrinkles including PDE5 inhibitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100030769 2010-04-05
KR10-2010-0030769 2010-04-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/645,182 Continuation US8716298B2 (en) 2010-04-05 2012-10-04 Composition for reducing skin wrinkles including PDE5 inhibitor

Publications (2)

Publication Number Publication Date
WO2011126250A2 WO2011126250A2 (ko) 2011-10-13
WO2011126250A3 true WO2011126250A3 (ko) 2012-03-08

Family

ID=44763374

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/002330 WO2011126250A2 (ko) 2010-04-05 2011-04-04 Pde5 억제제를 함유하는 피부 주름 개선용 조성물

Country Status (6)

Country Link
US (2) US8716298B2 (ko)
EP (1) EP2556820A4 (ko)
JP (2) JP2013523809A (ko)
KR (2) KR101377178B1 (ko)
CN (1) CN102970965A (ko)
WO (1) WO2011126250A2 (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2556820A4 (en) * 2010-04-05 2015-01-21 Sk Chemicals Co Ltd COMPOSITION CONTAINING PDE5 INHIBITOR FOR MITIGATION OF SKIN WRINKLES
WO2013036081A2 (en) * 2011-09-09 2013-03-14 Sk Chemicals Co., Ltd. Composition for reducing skin wrinkles including pde5 inhibitor
AT512084A1 (de) * 2011-10-20 2013-05-15 Univ Wien Tech Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren
CN105102447B (zh) * 2013-03-29 2017-08-25 山东轩竹医药科技有限公司 双环取代的嘧啶类pde‑5抑制剂的前药
TN2017000029A1 (en) 2014-08-12 2018-07-04 Mezzion Pharma Co Ltd Methods of improving myocardial performance in fontan patients using udenafil compositions
CN104530054B (zh) * 2014-12-19 2018-01-19 扬子江药业集团有限公司 盐酸优克那非的多晶型物及其制备方法
CN108409738B (zh) * 2017-02-10 2020-10-16 华东理工大学 3,4-亚甲二氧基苯基取代四氢-β-咔啉哌嗪二酮类衍生物及其用途
WO2019158572A1 (en) 2018-02-15 2019-08-22 Boehringer Ingelheim International Gmbh Inhibitors of trpc6
WO2021236891A1 (en) * 2020-05-20 2021-11-25 Augusta University Research Institute, Inc. Gut-targeted phosphodiesterase inhibitors
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
KR20230118137A (ko) * 2020-12-11 2023-08-10 일동제약(주) 안드로겐 수용체 및 포스포디에스테라아제 이중 억제제로서의신규 화합물
GB202208911D0 (en) * 2022-06-17 2022-08-10 Ravan Bio Limtied Treatments

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010016165A (ko) * 2000-11-16 2001-03-05 정순학 성기능 장애 치료를 위한 피부에 적용하는 제제
WO2001051042A2 (en) * 2000-01-11 2001-07-19 Pfizer Limited Treatment of diabetic ulcers
WO2002015893A2 (en) * 2000-08-21 2002-02-28 Pfizer Limited Treatment of wounds
WO2006042701A1 (de) * 2004-10-18 2006-04-27 Polymun Scientific Immunbiologische Forschung Gmbh Liposomale zusammensetzung einen wirkstoff zur relaxierung glatter muskulatur enthaltend, die herstellung dieser zusammensetzung und deren therapeutische verwendung

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
ATE213246T1 (de) 1997-11-12 2002-02-15 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren
KR100353014B1 (ko) 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
HU225917B1 (en) 1999-09-16 2007-12-28 Tanabe Seiyaku Co Pyrimidine and pyrazine derivatives, pharmaceutical compositions containing them and their use
KR100358083B1 (ko) 2000-02-17 2002-10-25 에스케이케미칼주식회사 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도
KR20020018566A (ko) * 2000-09-01 2002-03-08 액티브 올가닉스 인코포레이티드 모노-아실-(리소)-글리세롤인지질로 국소 활성의 효능을강화하는 방법 및 이의 용도
US20030216407A1 (en) * 2002-01-31 2003-11-20 Pfizer Inc. Use of PDE5 inhibitors in the treatment of scarring
GB0202254D0 (en) * 2002-01-31 2002-03-20 Pfizer Ltd Prevention of scarring
US20080317679A1 (en) 2002-10-25 2008-12-25 Foamix Ltd. Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses
TWI345571B (en) * 2005-03-23 2011-07-21 Ing Ming Chiu Acidic fibroblast growth factor 1 (fgf-1) used for skin caring
BRPI0504797B1 (pt) * 2005-10-27 2020-02-04 Pele Nova Biotecnologia S A formulação tópica, método de tratamento cosmético para rejuvenescimento da pele, método de tratamento cosmético e uso de uma formulação
NL2000291C2 (nl) * 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
EP2556820A4 (en) * 2010-04-05 2015-01-21 Sk Chemicals Co Ltd COMPOSITION CONTAINING PDE5 INHIBITOR FOR MITIGATION OF SKIN WRINKLES

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001051042A2 (en) * 2000-01-11 2001-07-19 Pfizer Limited Treatment of diabetic ulcers
WO2002015893A2 (en) * 2000-08-21 2002-02-28 Pfizer Limited Treatment of wounds
KR20010016165A (ko) * 2000-11-16 2001-03-05 정순학 성기능 장애 치료를 위한 피부에 적용하는 제제
WO2006042701A1 (de) * 2004-10-18 2006-04-27 Polymun Scientific Immunbiologische Forschung Gmbh Liposomale zusammensetzung einen wirkstoff zur relaxierung glatter muskulatur enthaltend, die herstellung dieser zusammensetzung und deren therapeutische verwendung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2556820A4 *

Also Published As

Publication number Publication date
EP2556820A4 (en) 2015-01-21
EP2556820A2 (en) 2013-02-13
US20140179701A1 (en) 2014-06-26
KR20110112212A (ko) 2011-10-12
WO2011126250A2 (ko) 2011-10-13
US9155691B2 (en) 2015-10-13
CN102970965A (zh) 2013-03-13
JP2016166228A (ja) 2016-09-15
KR20130085397A (ko) 2013-07-29
KR101377178B1 (ko) 2014-03-26
US8716298B2 (en) 2014-05-06
US20130030174A1 (en) 2013-01-31
JP2013523809A (ja) 2013-06-17

Similar Documents

Publication Publication Date Title
WO2011126250A3 (ko) Pde5 억제제를 함유하는 피부 주름 개선용 조성물
WO2011061330A3 (de) Verwendung physiologischer kühlwirkstoffe und mittel enthaltend solche wirkstoffe
WO2014037314A3 (en) Active compound combinations
WO2009089494A3 (en) Pharmaceutical compositions
WO2011073279A3 (fr) Procédé de traitement cosmétique impliquant un composé apte à condenser in situ
WO2012046030A3 (en) Phosphodiesterase inhibitors
WO2009090237A3 (en) Fungicide hydroximoyl-tetrazole derivatives
WO2013098416A3 (fr) Composes anti-douleur
WO2014037315A3 (en) Active compound combinations
WO2010072787A3 (en) A composition comprising a retinoid and method of treating skin conditions
WO2013057013A3 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
WO2011122872A3 (ko) 쿠메스트롤 또는 쿠메스트롤을 포함하는 콩 추출물 포함 조성물
WO2012104240A3 (de) Kosmetische verwendung
MY165041A (en) Composition for improving brain function and method for improving brain function
WO2011080254A3 (en) Fungicide hydroximoyl-heterocycles derivatives
WO2011073370A3 (fr) Utilisation du 2,3-dihydroxypropyl dodécanoate pour le traitement de la séborrhée
WO2013068960A3 (en) Monounsaturated fatty acid for nailcare
WO2012173382A3 (ko) 탄시논ⅱａ를 유효성분으로 함유하는 피부 외용제 조성물
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
WO2012082942A3 (en) Neuropeptide analogs, compositions, and methods for treating pain
WO2010075086A3 (en) Pyrrolidinone inhibitors of pde-4
WO2011026577A3 (de) Zubereitungen mit wasserunlöslichen polymeren aminen zur verminderung von körpergeruch
WO2010059639A3 (en) Hydroxyadamantyl inhibitors of dipeptidylpeptidase iv
WO2008125771A3 (fr) Utilisation cosmetique d'un extrait de debaryomyces hansenii
WO2013068962A3 (en) Monounsaturated fatty acid for nailcare

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180018099.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11766101

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2013503664

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2011766101

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011766101

Country of ref document: EP